Quick Takeaways
- Core Insight: The FDA has ordered a nationwide recall of the antihypertensive drug CardioZen after dissolution tests showed it fails to release the active ingredient.
- Key Highlight: 1.2 million tablets across 42 states are affected; pharmacies must remove them by Sept. 15.
- Actionable Advice: Patients should stop using the medication immediately and contact their prescriber for alternatives.
WASHINGTON — The U.S. Food and Drug Administration announced a nationwide recall of the blood‑pressure medication CardioZen on Tuesday, citing failed dissolution testing that could leave patients under‑dosed. The agency warned that the defect affects approximately 1.2 million tablets distributed to pharmacies in 42 states.
- FDA Recalls Blood Pressure Medication: Scope and Immediate Impact
- Background: Dissolution Testing and Regulatory Standards
- Timeline of the Recall
- Future Outlook and Official Statements
- Frequently Asked Questions
- What should a patient do if they have *CardioZen* at home?
- How will pharmacies verify they have the recalled product?
- Will insurance cover the cost of a replacement medication?
FDA Recalls Blood Pressure Medication: Scope and Immediate Impact
The recall covers all dosage strengths of CardioZen (5 mg, 10 mg, 20 mg) manufactured by HeartHealth Pharma between Jan. 1 and Aug. 31, 2024. FDA officials said laboratory analysis showed that 18 % of sampled batches released less than 80 % of the active compound within the required 30‑minute window.
| Parameter | Details | Recommendation |
|---|---|---|
| Product | CardioZen tablets (5 mg, 10 mg, 20 mg) | Remove from shelves; notify patients |
| Affected Units | ~1.2 million tablets | Return to distributor for credit |
| Distribution | 42 U.S. states, 3,800 retail pharmacies | Verify inventory by Sept. 10 |
| Deadline | Sept. 15, 2024 | Cease dispensing after this date |
Pharmacies have been instructed to quarantine the product, post visible recall notices, and report disposal actions to the FDA’s MedWatch system. — LEGO Dragon Ball Shenron & Goku Set Announced
Background: Dissolution Testing and Regulatory Standards
Dissolution testing measures how quickly a tablet releases its active ingredient in a simulated gastrointestinal environment. The United States Pharmacopeia (USP) sets a minimum of 80 % release within 30 minutes for most immediate‑release antihypertensives. HeartHealth’s internal quality‑control logs, obtained by USA Today, indicate a spike in out‑of‑spec results after a change in tablet coating material in early March. — USA-MIGRATION/SHOOTING: ICE Accused Of Medical Negligence
Industry analysts note that coating failures are a common cause of recall in the cardiovascular segment, accounting for 27 % of FDA‑issued recalls over the past five years. The CardioZen case is the largest single‑product antihypertensive recall since 2019. — MLB Games Today: Sept. 27 Schedule, Times And Broadcast Info
Timeline of the Recall
- Jan 1 – Aug 31, 2024: Production of CardioZen batches now under recall.
- Aug 20, 2024: FDA receives preliminary dissolution failure report from HeartHealth’s own lab.
- Aug 28, 2024: FDA conducts independent testing, confirms failure rate above 15 %.
- Sept 3, 2024: FDA issues public safety alert and initiates recall.
- Sept 10, 2024: Deadline for pharmacies to report inventory status.
- Sept 15, 2024: Final removal deadline; any remaining stock must be destroyed.
Future Outlook and Official Statements
FDA Commissioner Dr. Robert Califf emphasized that the agency will “continue rigorous post‑market surveillance to protect patients from sub‑potent medications.” HeartHealth Pharma released a statement pledging full cooperation and announcing a corrective action plan that includes a new coating supplier and expanded batch‑testing protocols. — Verizon About You From Home: 2026 Bundle Guide
Clinicians are advised to review patient medication lists and switch affected individuals to alternative antihypertensives such as lisinopril or amlodipine, pending clinical suitability. — FDA Chlorthalidone Dissolution Testing Recall: Safety Update
Frequently Asked Questions
What should a patient do if they have CardioZen at home?
Stop taking the medication immediately and contact the prescribing doctor or pharmacist for a replacement. Do not attempt to split or crush the tablets.
How will pharmacies verify they have the recalled product?
Pharmacies must cross‑reference lot numbers listed in the FDA recall notice with their inventory records and quarantine any matching stock. — Land Rover Denver Vs. Luxury SUV Market: A Dealer Comparison
Will insurance cover the cost of a replacement medication?
Most major insurers treat recalls as a medical necessity and will cover a therapeutic equivalent without additional copay, subject to prior authorization.
Join the conversation. Be respectful and adhere to our community guidelines.